Eledon Pharmaceuticals (ELDN) to Release Earnings on Thursday

Eledon Pharmaceuticals (NASDAQ:ELDN) will likely be releasing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 26, 2026 at 4:00 PM ET.

Eledon Pharmaceuticals Stock Performance

Eledon Pharmaceuticals stock opened at $2.74 on Tuesday. Eledon Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $4.60. The stock has a 50-day simple moving average of $2.25 and a 200 day simple moving average of $2.33. The stock has a market capitalization of $164.21 million, a P/E ratio of -2.58 and a beta of 0.84.

Institutional Trading of Eledon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC grew its holdings in Eledon Pharmaceuticals by 11.7% in the 2nd quarter. First Light Asset Management LLC now owns 2,600,498 shares of the company’s stock valued at $7,047,000 after buying an additional 271,730 shares in the last quarter. Ensign Peak Advisors Inc increased its position in Eledon Pharmaceuticals by 94.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 2,464,919 shares of the company’s stock worth $3,722,000 after buying an additional 1,200,000 shares during the period. Zimmer Partners LP lifted its holdings in shares of Eledon Pharmaceuticals by 30.6% during the fourth quarter. Zimmer Partners LP now owns 2,384,228 shares of the company’s stock worth $3,600,000 after buying an additional 559,228 shares in the last quarter. Sphera Funds Management LTD. lifted its holdings in shares of Eledon Pharmaceuticals by 97.4% during the fourth quarter. Sphera Funds Management LTD. now owns 2,132,131 shares of the company’s stock worth $3,220,000 after buying an additional 1,051,898 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at about $2,751,000. 56.77% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on ELDN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a report on Monday, December 29th. Guggenheim cut their target price on shares of Eledon Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.67.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.